Difference between revisions of "Sugemalimab (Cejemly)"
Jump to navigation
Jump to search
m |
m |
||
| Line 13: | Line 13: | ||
==History of changes in NMPA indication== | ==History of changes in NMPA indication== | ||
| − | *2022-06-06: Approved for the treatment of patients with unresectable stage III [[Non-small cell lung cancer|non-small cell lung cancer (NSCLC)]] whose disease has not progressed following concurrent or sequential platinum-based chemoradiotherapy. | + | *2022-06-06: Approved for the treatment of patients with unresectable stage III [[Non-small cell lung cancer|non-small cell lung cancer (NSCLC)]] whose disease has not progressed following concurrent or sequential platinum-based chemoradiotherapy. ''(Based on GEMSTONE-301)'' |
==Also known as== | ==Also known as== | ||
| Line 25: | Line 25: | ||
[[Category:Bladder cancer medications]] | [[Category:Bladder cancer medications]] | ||
[[Category:Non-small cell lung cancer medications]] | [[Category:Non-small cell lung cancer medications]] | ||
| − | [[Category:NMPA approved | + | [[Category:NMPA approved in 2022]] |
Revision as of 12:51, 26 June 2023
General information
Class/mechanism: PD-L1 blocking antibody. PD-L1 (programmed death-1 ligand 1) expressed on tumor cells and tumor-infiltrating immune cells can result in inhibition of anti-tumor immune responses.
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Toxicity management
Diseases for which it is used
History of changes in NMPA indication
- 2022-06-06: Approved for the treatment of patients with unresectable stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent or sequential platinum-based chemoradiotherapy. (Based on GEMSTONE-301)
Also known as
- Brand name: Cejemly